Community Data & Funding Resources

 

Community Data:

A community health assessment is a careful, systematic examination of the health status of the community that is used to identify key health problems and assets in the community. Data from the assessment will inform decision-making, prioritization of health problems and development of plans to improve the health of the community. The success of the CHA is owned and led by members of each community, so that the results accurately reflect the opinions of people who live, work, play, and pray in each community in the Commonwealth.

Community health assessments performed in the Central Shenandoah Health District are linked below:

Funding Opportunities:

Cycle 4 COVID-19 Vaccine Equity Program (uploaded 08/14/2023, Due 09/15/2023)

The Central Shenandoah Health District (CSHD) is seeking proposals from a diverse array of community organizations to support strategies that ensure greater equity and access to COVID-19 vaccine for those populations disproportionately affected by COVID-19.

Eligibility

Organizations applying for funding should be established nonprofit entities such as Community-Based Organizations (CBOs), Community Health Clinics/Centers, healthcare organizations, coalitions, Faith-Based Organizations, local government agencies, local educational agencies, etc., with a rapport in any priority populations(s) of focus and a demonstrated capacity to engage in relevant activities.

To be eligible for this grant, the organization must conduct operations in, or must be focused on addressing the community needs of, one or more of the following Virginia locations:  Cities of Buena Vista, Harrisonburg, Lexington, Staunton, Waynesboro and/or Counties of Augusta, Bath, Highland, Rockbridge, Rockingham.

Populations of Focus

  • People in racial and ethnic minority groups (Non-Hispanic American Indian, Alaska Native, Non-Hispanic Black, Hispanic)
  • People living in communities with high social vulnerability index
  • People living in rural communities
  • People with disabilities
  • People with who are homebound or isolated
  • People who are underinsured or uninsured
  • People who are immigrants and/or refugees
  • People with transportation limitations

Relevant Activities

  • Vaccine education and outreach
  • Improving access to COVID-19 vaccines by expanding and diversifying opportunities for getting vaccinated
  • Identifying and addressing social determinants/conditions to reduce barriers to vaccination

Period of Performance

Funding may commence upon full execution of a Subrecipient Agreement and continue through June 30, 2024, with no renewal options.

Funding Amounts

  • Minimum Request:  $10,000 per award
  • Maximum Request:  $50,000 per award

Number of Awards Anticipated

1 to 4 (as funds allow)

Important Dates

RFA Issued:    August 14, 2023

Application Closing Date:  Applications will be received and reviewed on a rolling basis, from the issue date through 4:00 pm EDT on Friday, September 15, 2023.

Announcement of Grantees is anticipated 2-3 weeks after submission of applications.

Application Materials:

Please download and read the Request for Application package (RFA# VDH-24-005-0013) carefully to learn more.  Application materials are available on eVA (https://eva.virginia.gov/) or download the materials below:

If you have any issues with downloading, contact Elise Wallace, Cycle 4 Grant Manager, elise.wallace@vdh.virginia.gov to obtain the required Application for Funding template and Budget Template. 

Contact:

For questions regarding this grant opportunity, please contact Elise Wallace, MPH, Cycle 4 Grant Manager:  elise.wallace@vdh.virginia.gov or 804-839-7517. Queries must be received no later than Thursday, September 7, 2023.

The Cycle 4 COVID-19 Vaccine Equity Program is supported by the National Center for Immunization and Respiratory Diseases of the Centers for Disease Control and Prevention, as part of a financial assistance award totaling $77,125,694 to the Virginia Department of Health, with 100 percent funded by the National Center for Immunization and Respiratory Diseases of the Centers for Disease Control and Prevention. The contents are those of the author and do not necessarily represent the official views of the CDC or the U.S. Government.